secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K/A
Filed at:   2026-08-07T10:41:57+00:00
Accession:  0001193125-26-339070
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Exec Chair Barbara Weber departs; severance, equity acceleration disclosed
--------------------------------------------------------------------------------

- Dr. Barbara Weber stepped down as Executive Chair and board member effective Aug 3, 2026; separation agreement executed Aug 6, 2026.
- Severance: base salary through Dec 31, 2026; COBRA reimbursement to Dec 31, 2026.
- Full acceleration of outstanding options and RSUs, subject to Compensation Committee approval; exercise period extended to Aug 3, 2027 or original expiry.
- Pro-rata 2026 annual incentive compensation paid by Mar 15, 2027, based on company and individual performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526339070/0001193125-26-339070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526339070/d215768d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-339070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer